Kangpu Biopharmaceuticals, Ltd Report issue

For profit Phase 1 Phase 2
Founded: Shanghai China (2011)

Organization Overview

First Clinical Trial
2018
NCT03569280
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2020

Timeline

NOW
  • Now

Alternative names

Kangpu Biopharmaceuticals, Ltd. | Kangpu Biopharmacuticals | Sr. Director, Clinical Operations

Active Ingredients

Drugs in Phase 2 Trials (1)

kpg-818 (3 trials)

Drugs in Phase 1 Trials (3)

abiraterone (zytiga) (1 trial)

apalutamide (erleada) (1 trial)

enzalutamide (xtandi) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Lupus Erythematosus, Systemic (Phase 1)

Neoplasms (Phase 1)

Prostatic Neoplasms (Phase 1)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 4
  • # of Trial APIs: 4